Foxp3+ T regulatory (Treg) cells suppress immune cell activation and establish normal immune homeostasis. How Treg cells maintain their identity is not completely understood. Here we show that Ndfip1, a coactivator of Nedd4-family E3 ubiquitin ligases, is required for Treg cell stability and function. Ndfip1 deletion in Treg cells results in autoinflammatory disease. Ndfip1-deficient Treg cells are highly proliferative and are more likely to lose Foxp3 expression to become IL-4-producing TH2 effector cells. Proteomic analyses indicate altered metabolic signature of Ndfip1-deficient Treg cells and metabolic profiling reveals elevated glycolysis and increased mTORC1 signalling. Ndfip1 restricts Treg cell metabolism and IL-4 production via distinct mechanisms, as IL-4 deficiency does not prevent hyperproliferation or elevated mTORC1 signalling in Ndfip1-deficient Treg cells. Thus, Ndfip1 preserves Treg lineage stability and immune homeostasis by preventing the expansion of highly proliferative and metabolically active Treg cells and by preventing pathological secretion of IL-4 from Treg cells.
Foxp3+ regulatory T (Treg) cells suppress spontaneous immune cell activation and limit effector cell function, thereby preventing autoimmune and inflammatory disorders1,2. While generally stable, Treg lineage cells can have a high degree of instability in inflammatory settings. Treg cell instability is characterized by the loss of suppressive function, loss of Foxp3 protein or gain of pro-inflammatory cytokine production3,4. Defining pathways that help to establish and maintain Foxp3 expression, promote Treg cell suppressive function, prevent Treg cell production of pro-inflammatory cytokine and/or maintain Treg cell numbers will aid in the development of new Treg cell-based therapeutic applications.
Appropriate regulation of cellular energetics and metabolism is important for Treg cell function and lineage stability5. Unlike effector T cells, which rely heavily on glycolysis, Treg cells rely on fatty acid oxidation for their energy needs6. Mechanistic target of rapamycin (mTOR) is a serine–threonine kinase that forms part of the mTORC1 and mTORC2 protein complexes and is a critical regulator of cellular metabolic processes. Both complexes can limit glycolysis in Treg cells thereby promoting lineage stability and suppressive functions7,8. Although metabolic state is clearly important for Treg maintenance and function, many factors that impact Treg cell metabolism remain unknown.
Ubiquitylation is a fundamental post-translational modification affecting many aspects of T-cell differentiation and function9,10. Neural precursor cell expressed, developmentally downregulated 4 (Nedd4) family interacting protein 1 (Ndfip1) is a transmembrane protein that binds and activates Nedd4 family E3 ubiquitin ligases11. The highly conserved catalytic E3 ligases perform two functions in protein ubiquitylation: binding to the specific ubiquitylation target and catalysing the final transfer of ubiquitin. Ndfip1 activation of the Nedd4 E3 ligase Itch results in ubiquitylation and degradation of the transcription factor JunB, thereby limiting interleukin (IL)-4 cytokine production from T helper type 2 (TH2) cells and TH2-mediated inflammatory disease12,13.
Ndfip1-deficient mice have decreased Treg cell numbers in the small bowel, a site of peripheral Treg generation, likely due to increased IL-4 signalling, which is inhibitory to Treg differentiation14. However, whether Ndfip1 also modulates Treg function after cells have committed to the Treg cell lineage has not been explored. Given that Treg-specific deletion of Itch results in a TH2-biased autoinflammatory disease15, it seems plausible that Ndfip1 might be required to support Itch function in Treg cells.
Here we show that Ndfip1 expression in Treg cells prevents spontaneous inflammation at several sites, such as the lungs and skin. Ndfip1 limits both the accumulation and proliferation of CD44+ effector Treg cells and prevents Treg cell production of IL-4. Consistent with increased proliferation and exposure to IL-4, Treg cells lacking Ndfip1 show increased conserved non-coding DNA sequence 2 (CNS2) methylation and are prone to losing Foxp3 expression in vivo. Increased T-cell proliferation is associated with increased mTORC1 signalling and high glycolytic activity, metabolic programmes that can fuel effector function in Treg cells and contribute to Treg lineage instability. Thus Ndfip1 maintains lineage identity in Treg cells and prevents these cells from aberrant acquisition of effector T-cell function. Ndfip1 is therefore a critical molecular sentinel that prevents autoinflammatory disease.
Treg-specific loss of Ndfip1 results in inflammation
Ndfip1−/− mice develop a severe autoinflammatory disease by 6 weeks of age, resulting in death12,16. While thymic Treg output in Ndfip1-deficient mice is not altered14, Treg cell numbers are reduced at the sites of peripheral Treg induction14. Therefore, to test the role of Ndfip1 within committed Treg cells, we generated mice in which Ndfip1 is conditionally deleted in Treg cells using the Foxp3-Cre-YFP reporter mice17. We observed that Ndfip1 mRNA is induced upon stimulation of control Ndfip1+/+Foxp3-Cre-sorted YFP+ Treg cells and that Ndfip1 message is effectively ablated in Treg cells from Ndfip1fl/fl Foxp3-Cre male mice, which lack Ndfip1 in all Treg cells (Fig. 1a).
By 9–16 weeks of age, Ndfip1fl/fl Foxp3-Cre male mice developed pronounced splenomegaly, lymphadenopathy and progressive dermatitis (Fig. 1b). Histologically, the skin, oesophagus and lung showed marked immune infiltration inflammation (Fig. 1b). Analysis of spleen weight-to-body weight ratios revealed that male Ndfip1fl/fl Foxp3-Cre mice showed evidence of lymphoid expansion (Fig. 1c). To determine which immune responses were contributing to the observed inflammation, we examined serum immunoglobulin (Ig) levels. We found elevated levels of IgE and IgG1, indicative of type 2 inflammation, as well as elevated IgM (Fig. 1d). To determine the contribution of CD4 T cells to this pathology, we examined the spleen and lung of the mice and found increased activated phenotype (CD44+) CD4 T cells (Fig. 1e). CD4 T cells present in the lung of male Ndfip1fl/fl Foxp3-Cre animals were more likely to express the effector cytokines interferon-γ (IFNγ), IL-4 and IL-17A upon ex vivo stimulation (Fig. 1f). These data suggested that Ndfip1 expression in Treg cells is required for suppression of tissue inflammation and pathology.
Ndfip1fl/fl Foxp3-Cre mice have more CD44+ eTreg cells
The observed pathology could result from a loss of Treg cell numbers (as occurs with mice lacking Foxp318) or Treg cell function (as is seen in Treg cell-specific CTLA4 deficiency19). We therefore examined Treg percentages and numbers in the spleens and lung of Ndfip1fl/fl Foxp3-Cre and controls. Surprisingly, Treg cell numbers were increased in Ndfip1fl/fl Foxp3-Cre animals (Fig. 2a–c). Further, analysis of the Treg cell effector proteins—inducible T-cell costimulator (ICOS), programmed cell death-1 (PD-1) and glucocorticoid-induced TNFR-related protein (GITR)—revealed increased expression on Treg cells from Ndfip1fl/fl Foxp3-Cre male mice compared to Cre+ controls (Fig. 2d). We did not see marked changes in CD25 levels. Taken together, these data suggest that the immunopathology observed in Ndfip1fl/fl Foxp3-Cre male mice is not due to decreased Treg numbers or loss of effector proteins known to support Treg function.
Treg cells can be quiescent or activated; these two subsets can be distinguished by the expression of CD44 and CD62L (ref. 20). Analysis of the lung of male Ndfip1fl/fl Foxp3-Cre mice revealed an increase in frequency (Fig. 2e,f) and numbers (Fig. 2g) of Foxp3+ cells with an activated or ‘effector’ (eTreg) phenotype (CD62LloCD44+). In contrast, Ndfip1fl/fl Foxp3-Cre and control mice contained equivalent numbers of cells with a quiescent or ‘central’ (cTreg) phenotype (CD62LhiCD44−) (Fig. 2g). ICOS, PD-1 and GITR are more highly expressed on eTreg cells. In contrast, CD25 is particularly high on cTreg cells20. Thus the observed increase in surface expression of ICOS, PD-1 and GITR observed on total Treg cells from Ndfip1fl/fl Foxp3-Cre animals could be due to an increased proportion of eTreg cells. To assess this, we examined the surface expression of ICOS, GITR, CD25 and PD-1 on the eTreg and cTreg populations. cTreg cells, as expected, had low levels of ICOS, GITR and PD-1, and loss of Ndfip1 did not alter this (Fig. 2h). However, cTreg cells from Ndfip1fl/fl Foxp3-Cre mice had decreased levels of CD25. Strikingly, in addition to their increased frequency, eTreg cells from Ndfip1fl/fl Foxp3-Cre mice showed higher levels of ICOS, GITR, CD25 and PD-1 compared to wild-type (WT) counterparts (Fig. 2h).
cTreg cells are thymically derived and undergo peripheral conversion to eTreg cells under the instruction of T-cell receptor (TCR) stimulation and ICOS stimulation20. Therefore, observing increased frequency and number of eTreg cells could indicate either increased conversion of cTreg cells or expansion of eTreg cells. An increased cTreg conversion rate would be expected to decrease the numbers of cTreg cells, unless compensated for by thymic output. As there was no decrease in the peripheral numbers of cTreg cells in Ndfip1fl/fl Foxp3-Cre male mice, we next examined thymic output utilizing mixed bone marrow chimera animals in which WT (Ndfip1+/+ Foxp3-Cre) and Ndfip1fl/fl Foxp3-Cre Treg cells develop in the same environment to control for effects of inflammation. In control and mixed chimeras, total Treg thymic output was unchanged (Supplementary Fig. 1a). Furthermore, within the mixed chimeras there was no significant difference in the percentge of thymic Treg cells derived from Ndfip1-sufficient or -deficient cells relative to the observed reconstitution ratio of all thymic CD4+ T cells (Supplementary Fig. 1b). This suggests that the increase in eTreg, but not in cTreg, cell number in the periphery is not due to an altered rate of cTreg cell conversion to eTreg cells.
Decreased suppressive function of Treg cells is known to lead to inflammation. Therefore, we examined Treg cell function. In vitro, Ndfip1-deficient and WT Treg cells suppressed proliferation of WT T conventional (Tconv) cells to the same degree (Supplementary Fig. 1c,d). We then examined Treg cell function in vivo using a model of T-cell transfer-induced colitis. Similar to our results from the in vitro assays, Ndfip1-deficient and WT Treg cells were equally able to prevent weight loss due to inflammation caused by cotransferred Tconv cells (Supplementary Fig. 1e). These data support that the pathology observed in Ndfip1fl/fl Foxp3-Cre mice is not due to a loss of Treg number or an overall loss of Treg cell-suppressive function.
Ndfip1 limits Treg proliferation and levels of ICOS and GITR
The expansion of CD44+ eTreg cells in male Ndfip1fl/fl Foxp3-Cre animals in the absence of robust changes in cTreg cells suggested that Ndfip1 restricts eTreg cell numbers. Additionally, our data supported that Ndfip1 limits the expression of ICOS, GITR, CD25 and PD-1 on eTreg cells. However, both expansion and phenotype of eTreg cells could be altered in inflammatory environments, independent of an intrinsic role for Ndfip1. To distinguish between these possibilities, we examined Ndfip1fl/fl Foxp3-Cre+/− female animals. These mice have mixtures of WT (YFP-Cre−) and Ndfip1-deficient (YFP-Cre+) Foxp3+ Treg cells, due to X chromosome inactivation, that can be distinguished by the expression of the YFP Cre reporter.
Surprisingly, despite the presence of WT Treg cells, female Ndfip1fl/fl Foxp3-Cre+/− mice had similar inflammatory burden, as defined by the ratio of spleen weight to body weight (Supplementary Fig. 2a) and contained equally high percentages of IFNγ-, IL-4- and IL-17A-expressing CD4 T cells, as the males (Supplementary Fig. 2b). Compared to male animals, which are uniformly sick beyond 16 weeks of age, female animals had lower incidence of skin dermatitis. Ndfip1fl/fl Foxp3-Cre+/− mice contained increased numbers of total lung Treg cells compared to Ndfip1+/+ Foxp3-Cre +/− counterparts (Fig. 3a,b). Similar to their male counterparts, female animals had total lung Treg cells that were skewed towards the eTreg phenotype (Fig. 3c,d). In control Ndfip1+/+ Foxp3-Cre +/− female mice, Foxp3-Cre+ (YFP+) cells were outnumbered by Foxp3-Cre− (YFP−) cells by almost 1:3, indicating an effect of Cre expression (Fig. 3f). Surprisingly, in Ndfip1fl/fl Foxp3-Cre+/− females, this ratio was skewed towards YFP+ cells, supporting an in vivo competitive advantage of Ndfip1-deficient Treg cells (Fig. 3f).
To identify intrinsic effects of Ndfip1 deficiency on Treg cells, in each female animal, for each parameter examined, we first determined the ratio of the value for YFP+-to-YFP− Treg cells to normalize for an effect of Cre. Then we compared this ratio between Ndfip1fl/fl Foxp3-Cre+/− and Ndfip1+/+ Foxp3-Cre+/− animals. Our analysis revealed that Ndfip1-deficient Treg cells were significantly more likely to display an eTreg phenotype (CD44+CD62Llo) (Fig. 3g). Furthermore, expression of the proliferative marker Ki67 (Fig. 3h) was increased in Ndfip1-deficient eTreg cells. eTreg cells lacking Ndfip1 also had significantly higher levels of ICOS (Fig. 3i) and GITR (Fig. 3j). Thus Ndfip1 restricts eTreg numbers by limiting their proliferation and their expression of ICOS and GITR. However, levels of CD25 and PD-1 were similar to controls (Fig. 3k,l), suggesting that these markers were not directly affected by the loss of Ndfip1 in Treg cells.
The expression of activation markers on Treg cells is known to increase under inflammatory settings20. To determine how inflammatory conditions could influence control Treg cells, we looked at the expression of surface markers on CD44+ YFP− Treg cells from the Ndfip1+/+ Foxp3-Cre+/− females or from the inflamed environment in Ndfip1fl/fl Foxp3-Cre+/− female mice. CD44+ YFP− Treg cells from Ndfip1fl/fl Foxp3-Cre+/− mice showed increased expression of ICOS, GITR, CD25 and PD-1 (Supplementary Fig. 2c–f). Taken together with the data in Figs 2 and 3, this supports that the changes in CD25 and PD-1 expression in male Ndfip1fl/fl Foxp3-Cre mice are secondary to inflammation and that while inflammation can increase levels of ICOS and GITR, Ndfip1 is also an intrinsic regulator of ICOS and GITR on Treg cells (Supplementary Fig. 2g).
To further address whether the changes observed in the Ndfip1-deficient Treg cells were driven by inflammation, we looked in neonatal mice before the onset of overt inflammation. In 13-day-old female neonates, we found no differences between Ndfip1fl/fl Foxp3-Cre+/− and Ndfip1+/+ Foxp3-Cre+/− animals in spleen weight (Supplementary Fig. 3a), inflammation index (Supplementary Fig. 3b), total lung Foxp3+ Treg cell number or cytokine-producing CD4 T cells (Supplementary Fig. 3c,d). However, lungs from Ndfip1fl/fl Foxp3-Cre+/− female mice contained greater frequencies of YFP+ Treg cells (Supplementary Fig. 3e) and greater frequencies of eTreg cells (Supplementary Fig. 3f). Further, these eTreg cells showed higher expression of ICOS and GITR (Supplementary Fig. 3g,h). This further supports that Ndfip1 limits eTreg cell frequency and expression of ICOS and GITR in an intrinsic manner.
Ndfip1 limits IL-4 production by Treg cells
Our data indicate that Ndfip1 limits eTreg cell expression of ICOS and GITR and restricts eTreg cell proliferation. However, it remained unclear why Ndfip1fl/fl Foxp3-Cre+/− females developed inflammation, when approximately half of the Treg cells in these mice are Ndfip1 sufficient. This suggested a pathological gain of function in Ndfip1-deficient Treg cells. We thus investigated whether Ndfip1-deficient Treg cells could contribute to the pool of cytokine-producing cells in the lung of Ndfip1fl/fl Foxp3-Cre male mice shown in Fig. 1. Effector cytokine production by WT Treg cells is relatively rare but has been described under inflammatory21 or lymphopenic settings22,23. Strikingly, while WT Treg cells did not produce any IL-4 upon ex vivo stimulation, Ndfip1-deficient Treg cells could produce IL-4, and this was detectable at both the protein (Fig. 4a,b) and mRNA levels (Fig. 4c). Ndfip1-deficient Treg cells were also more likely to produce IL-10, IFNγ and IL-17A relative to WT controls. To determine whether the cytokine production was due to the loss of Ndfip1 or tied to the inflammatory environment, we generated mixed bone marrow chimeras. Consistent with our data from the female mice, these mixed chimeras developed dermatitis 8 weeks after reconstitution. Upon restimulation of lung homogenate, CD45.1+ WT Foxp3+ cells did not produce any IL-4 while CD45.2+ Ndfip1-deficient Foxp3+ cells in the same host could produce IL-4 (Fig. 4d,e), supporting an intrinsic role for Ndfip1 in limiting IL-4 production from Treg cells. Surprisingly, when we analysed the Foxp3− Tconv cells, we found a significant population of CD45.2+ cells that also expressed IL-4 (Fig. 4f,g), raising the possibility that the IL-4-producing population originated from Ndfip1fl/fl Foxp3-Cre Treg cells that had lost Foxp3.
Ndfip1-deficient Treg cells lose Foxp3 expression
Given the IL-4 production by Ndfip1-deficient Treg cells and their increased proliferative capacity, we posited that these cells would be likely to become methylated at their Foxp3 locus and become unstable. IL-4 receptor signalling in Treg cells, via signal transducer and activator of transcription factor 6 (STAT6), results in the methylation of the CNS2 region of the Foxp3 locus and repression of Foxp3 gene expression24. Therefore, we compared the methylation at 12 Cytosine-phosphate-guanine (CpG) islands in the Foxp3 CNS2 region in Ndfip1-sufficient and -deficient Treg cells, as well as WT Tconv cells. As expected, the CNS2 CpG motifs were predominantly methylated in Tconv cells (Supplementary Fig. 4a)24. Both WT and Ndfip1-deficient Treg cells had unmethylated CpG motifs in their Foxp3 promoter regions (Supplementary Fig. 4b), consistent with their expression of Foxp3 mRNA (Supplementary Fig. 4c). However, in Ndfip1fl/fl Foxp3-Cre Treg cells, there was an increase in methylation at the 12 examined CNS2 CpG sites, compared to WT Treg cells, which remained unmethylated at these sites (Fig. 5a,b).
These data suggested that Ndfip1 deficiency, via concomitant expression of IL-4, negatively impacts lineage stability of Treg cells. To test whether Ndfip1-sufficient and -deficient Treg cells have differential responses to destabilizing cytokines, we cultured Ndfip1-sufficient and -deficient Foxp3+ cells in stabilizing (IL-2) or destabilizing (IL-4 plus anti-IL-2) conditions and analysed Foxp3 protein expression as a surrogate for lineage stability. We found that Ndfip1-deficient Treg cells were equally stabilized by IL-2 and destabilized by IL-4 compared to their Ndfip1-sufficient counterparts (Supplementary Fig. 4d,e). Thus Ndfip1-deficient Treg cells are not uniquely sensitive to the destabilizing effects of IL-4; in vivo, however, Ndfip1-deficient IL-4 producing Treg cells are more likely to encounter destabilizing cytokine milieus.
To test Treg lineage stability in vivo, we sorted WT or Ndfip1-deficient CD45.2+ YFP+ Treg cells and cotransferred them with sorted naive CD45.1+ WT Tconv cells into Rag1−/− hosts (Fig. 5c). As we had previously observed (Supplementary Fig. 1e), mice receiving either Ndfip1-deficient or -sufficient Treg cells did not develop colitis (Supplementary Fig. 5a). At harvest, we determined the frequencies of CD45.2+ cells that were still Foxp3+ (current Treg cells) or that had lost Foxp3 (former Treg cells). In mice that received WT Treg cells, on average, 30% had lost Foxp3, similar to previous reports by other groups8,22. Strikingly, in mice that had received Ndfip1-deficient Treg cells, 60% on average had lost expression of Foxp3 (Fig. 5d,e). These Foxp3− CD45.2+ cells could represent Ndfip1-deficient Treg cells that had lost Foxp3 expression in vivo or a very proliferative Tconv cell contamination from cell sorting. If the Foxp3− cells represented former Treg cells, they would lack Ndfip1 mRNA, due to excision following the expression of Foxp3-Cre. Contaminating Tconv cells, on the other hand, would continue to express Ndfip1. We sorted current Treg cells, former Treg cells and Tconv cells and stimulated to induce the Ndfip1 mRNA expression. We found that the WT Tconv cells expressed Ndfip1 mRNA, while neither the Ndfip1fl/flFoxp3-Cre+ current Treg cells nor former Treg cells expressed detectable levels of Ndfip1 mRNA (Supplementary Fig. 5b). Thus Treg cells lacking Ndfip1 were more likely to lose Foxp3 expression than their WT counterparts.
Current (Fig. 5f) and former (Fig. 5g) Treg cells lacking Ndfip1 produced IL-4, while current and former WT Treg cells did not. Importantly, none of the WT Tconv cells produced IL-4 (Fig. 5h). This was not true for all cytokines since WT and Ndfip1-deficient cells were equally likely to make IFNγ regardless of whether they were Treg cells (Supplementary Fig. 5c,d) or cotransferred Tconv cells (Supplementary Fig. 5e).
Additionally, compared to WT Treg cells, Ndfip1-deficient Treg cells expanded to greater numbers in vivo (Supplementary Fig. 5f,g) suggesting an advantage in proliferation and/or survival of both current and former Ndfip1-deficient Treg cells. However, at steady state, it is likely that only a small percentage of Ndfip1fl/flFoxp3-Cre+ Treg cells are actively losing their Foxp3 at any point of time. In support of this, Ndfip1-deficient total Treg cells, eTreg cells and cTreg cells from female animals do not show a decrease in Foxp3 mean fluorescence intensity at steady state (Supplementary Fig. 6).
In summary, in a setting where Treg cells are pushed to undergo lymphopenia-induced proliferation, Ndfip1-deficient Treg cells have an advantage in growth and expansion, which leads to a large increase in total numbers of Ndfip1-deficient current and and former Treg cells. Since the majority of Ndfip1-deficient former Treg cells (∼50%) produce IL-4, this may explain the dramatic loss of Foxp3 observed in vivo.
IL-4 is dispensable for Ndfip1-deficient eTreg expansion
To assess whether IL-4 is required for the phenotypic changes in Treg cells lacking Ndfip1, we examined Treg cells in mice that lack both Ndfip1 and IL-4 (Ndfip1 IL-4 double knockout or DKO mice)25. These animals do not show the overt signs of inflammation such as dermatitis25,26 observed in age-matched Ndfip1fl/fl Foxp3-Cre animals. We observed increased frequencies of Treg cells (Supplementary Fig. 7a,b) compared to IL-4-deficient controls. The Ndfip1-deficient Treg cells that lacked IL-4 were more proliferative than controls, as determined by Ki67 (Supplementary Fig. 7c). Similar to the Ndfip1fl/fl Foxp3-Cre mice, Treg cells in the Ndfip1 IL-4 DKO mice were predominantly eTreg cells (Supplementary Fig. 7d,e). Additionally, the Ndfip1- and IL-4-deficient eTreg cells expressed higher levels of Ki67 (Supplementary Fig. 7f) and ICOS (Supplementary Fig. 7g) relative to control eTreg cells. Thus, while IL-4 from current and former Treg cells likely contributes to the inflammation observed in Ndfip1fl/fl Foxp3-Cre mice, increased Treg cell activation, proliferation and ICOS expression are not due solely to IL-4 signalling. Thus IL-4 is insufficient to explain the increased fitness of Ndfip1-deficient Treg cells.
Ndfip1-deficient eTreg cells have altered metabolic activity
To identify molecular pathways underlying the increased proliferation and altered eTreg cell phenotype of Ndfip1 deficient Treg cells, we used label-free quantitative proteomics to compare WT and Ndfip1-deficient cTreg and eTreg cells. We sorted YFP+ eTreg and cTreg cells from young WT or Ndfip1fl/fl Foxp3-Cre male mice, subjected these cells to liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis and quantified protein abundance using intensity-based absolute quantification27,28,29 (Fig. 6a). We achieved good reproducibility of identified proteins across three experiments, pooling two to three mice of each genotype per experiment (Fig. 6b). Comparing proteins identified in control eTreg and cTreg proteomes, our data fit well with what has been published previously on proteins unique to each subtype. Namely, among proteins that were significantly more abundant in cTreg than eTreg proteomes or that were found exclusively in cTreg proteomes, defined here as having a cTreg ‘bias’, we identified CD62L and Bcl2 (ref. 20) (Fig. 6c, Supplementary Data 1). Proteins that were increased in, or biased toward, the eTreg proteome included CD44 and several proteins associated with eTreg cells, such as Integrin alpha E/itgae (CD103)30 (Fig. 6c, Supplementary Data 1).
To characterize differential protein expression in Ndfip1-sufficient and -deficient Treg cells, we compared the ratio of protein abundance in eTreg:cTreg for each of the three experiments. This revealed widespread changes in the proteomes of Ndfip1-deficient Treg cells. Given that Ndfip1 deficiency drove changes predominantly in eTreg cells, we focussed our comparisons on the levels of proteins identified in WT and Ndfip1-deficient eTreg cells (Supplementary Data 2 and Fig. 6d). Our flow cytometric finding of increased GITR expression was supported by these Treg proteomes (Supplementary Data 2 and Fig. 6d). Surprisingly, proteins associated with increased mTORC1 activity were increased in Ndfip1-deficient eTreg cells. This included Lamtor1 (Fig. 6d), as well as the V-ATPase subunit d1 and Lamtor3, which are components of the v-ATPase-regulator complex that drives mTORC1 activation in cells31,32,33. We then performed network visualization of gene-ontology (GO) enrichment analysis for differentially regulated proteins in Ndfip1-sufficient and -deficient eTreg cells and identified clusters of nodes relating to metabolic processes that were significantly enriched (Fig. 6e and Supplementary Data 2). Pathway analysis further supported changes in the metabolic state of Ndfip1-deficient eTreg cells and, more specifically, an increase in mTORC1 activity. Thus loss of Ndfip1 led to an altered proteomic profile indicative of altered metabolic activity.
Ndfip1-deficient Treg cells have increased glycolysis
Based on this proteomics profiling, we sought to analyse the metabolic capacity of Ndfip1-deficient Treg cells. To obtain sufficient cell numbers for metabolic testing, we used in vitro IL-2-expanded Treg cells. We evaluated the bioenergetics of these expanded WT and Ndfip1fl/fl Foxp3-Cre Treg cells at ‘rest’ and also upon restimulation. We measured the extracellular acidification rate under glycolytic stress conditions (Fig. 7a–d) and oxygen consumption rate under mitochondrial stress conditions (Fig. 7e–h). Prior to stimulation, WT Treg cells had low basal rates of glycolysis, but rates increased when cells were stimulated (Fig. 7a,b). In Ndfip1-deficient Treg cells, the ‘resting’ glycolytic rate was only modestly increased over WT cells (Fig. 7a,c). However, restimulated Ndfip1-deficient Treg cells had a considerably increased glycolytic rate and glycolytic capacity compared to restimulated WT Treg cells (Fig. 7b–d). To assess mitochondrial function, we measured cell respiratory control, which is a general test of mitochondrial function in cells. Loss of Ndfip1 did not change the maximum respiratory capacity of Treg cells and caused a slight decrease in the spare respiratory capacity of Treg cells (Fig. 7e–h). Taken together, these data indicate that the loss of Ndfip1 drives a metabolic switch in activated Treg cells, promoting a more effector cell-like reliance on glycolysis to supply cellular energetic demands.
Ndfip1-deficient Treg cells have elevated mTORC1 activity
Effector T cells utilize glycolysis while Treg cells are more dependent on oxidative phosphorylation as their main source of energy34,35,36,37,38. High glycolytic activity in Treg cells, as can occur when mTORC1 activity is increased, has been associated with Treg cell dysfunction6,7,39. To investigate whether mTORC1 activity was increased in Ndfip1-deficient Treg cells, we cultured WT and Ndfip1fl/fl Foxp3-Cre Treg cells in vitro. We found that Ndfip1fl/fl Foxp3-Cre Treg cells quickly outnumbered their WT counterparts (Fig. 8a), were increased in cell size (Fig. 8b) and proliferated more (Fig. 8c). This, together with observed increases in ICOS and GITR expression (Fig. 8d,e), suggested that this in vitro culture system recapitulates the phenotype of Ndfip1-deficient Treg cells in vivo. Given that ICOS can be driven by mTORC1 (ref. 39) activity, we examined other proteins in the mTORC1 pathway, including the amino acid transporter, CD98, and phosphorylated S6 (pS6). CD98 and pS6 (Fig. 8f,g) were both increased in Ndfip1fl/fl Foxp3-Cre Treg cells. Coculture confirmed that these changes are not directly linked to IL-4 signalling (Fig. 8h).
Increased responsiveness to IL-2 could explain the fitness of Ndfip1-deficient Treg cells in this IL-2 expansion system. To test this, we sorted Ndfip1-sufficient and -deficient Treg cells and rested them overnight without cytokine or TCR stimulation. Upon brief IL-2 stimulation, we detected STAT5 phosphorylation (pSTAT5) by flow cytometry. pSTAT5 levels (mean fluorescence intensity) were similar between WT and Ndfip1-deficient Treg cells before and after IL-2 stimulation (Supplementary Fig. 8). This is consistent with our recent report showing that both Ndfip1 and its homologue, Ndfip2, are required in Tconv cells to drive the degradation of Jak1 and decrease STAT5 phosphorylation in response to IL-2 (ref. 40). Therefore, the increased metabolic activity of Ndfip1fl/flFoxp3-Cre+ Treg cells is cell intrinsic and not just because of enhanced responsiveness to IL-2.
Therapies using adoptively transferred Treg cells or that target Treg cell function are now being developed, making it essential to understand mechanisms that maintain Treg cell identity and how these pathways integrate with TCR activation and cellular metabolic processes. Our data identify Ndfip1, an activator of E3 ubiquitin ligases, as a new molecular target impacting Treg stability and function. We demonstrate that Ndfip1-deficient Treg cells are highly proliferative and concomitantly gain the capacity to produce the proinflammatory cytokine IL-4. Importantly, Ndfip1 deficiency can lead to the expansion of Treg cells and loss of Foxp3 in vivo.
Both mTORC1 and mTORC2 play important functions in preventing Treg cells from adopting a glycolytic metabolic profile. mTORC1-mediated glycolytic activity in Treg cells is modulated by the serine–threonine phosphatase, PP2A, and by the autophagy proteins, Atg5 and Atg7 (refs 7, 8). The lipid phosphatase, PTEN, inhibits mTORC2-mediated metabolic pathways in Treg cells to prevent Treg cell instability and maintain suppression of Th1 and Tfh effector T-cell functions41,42. Ndfip1-deficient Treg cells have increased protein levels of ICOS, CD98 and pS6, all indicators of high mTORC1 signalling. mTORC1 deletion in Treg cells leads to defects in efficiently synthesizing lipids from glucose and to defects in homeostatic proliferation in vivo39. Therefore, it is not surprising that Ndfip1-deficient Treg cells, with high mTORC1 signature, show greater homeostatic expansion in vivo, show greater metabolic fitness in vitro and in vivo and are more efficient at glycolysis. This altered glycolytic metabolism fuels dysfunction in vivo by driving the expansion of eTreg cells that are prone to produce IL-4 and lose Foxp3.
We propose that Treg cells lacking Ndfip1 progress through a series of changes that is precipitated by increased proliferation of activated (CD44+) Treg cells and accompanied by the acquisition of IL-4 production. These changes are likely initiated in eTreg cells since Ndfip1 is inducibly expressed upon T-cell activation. The elevated glycolytic metabolism in these cells drives further expansion of IL-4-producing current and former Treg cells. Autocrine IL-4 signalling can then lead to loss of Foxp3. Supporting this, CD44+ Ndfip1-deficient Treg cells have increased methylation at the CNS2 region of the Foxp3 locus, indicating susceptibility towards instability. Ndfip1-deficient TH2 cells are capable of driving tissue damage and inflammation as already described by our laboratory and others12,14,40,43.
Loss of IL-4 did not affect the activation, proliferation and in vivo expansion of Ndfip1-deficient Treg cells leading us to conclude that the metabolic fitness in Ndfip1-deficient Treg cells precedes or is independent of the gain in Treg cell-intrinsic IL-4 production. Furthermore, IL-4-overexpressing transgenic mice have been described and have increased recruitment of different immune cell subsets into the skin but do not develop spontaneous dermatitis44 as observed in Ndfip1fl/fl Foxp3-Cre mice. Last, loss of the mTORC1 subunit, Raptor, in Treg cells does not lead to a cell-intrinsic increase in Treg cell IL-4 or other effector cytokines39, suggesting that cytokine regulation and metabolic regulation by Raptor in Treg cells may be two independent events39. An attractive hypothesis that warrants further future investigation is whether two parallel (but perhaps cross-talking) cellular pathways are regulated by Ndfip1: one which dampens mTORC1 activity and glycolysis in order to limit Treg cell activation and proliferation, and a second that limits Treg cell IL-4 production. These pathways, though independent, may cooperate to account for the severity of the inflammation observed in Ndfip1fl/fl Foxp3-Cre mice.
Ndfip1 is a known activator of Itch40,45,46. Mice bearing a Treg-specific deletion of Itch show some overlapping features with the Ndfip1fl/fl Foxp3-Cre mice described here15: Itch-deficient Treg cells have an effector Treg cell phenotype, an increase in proliferation and intact suppression in traditional in vivo and in vitro suppression assays. Itch-deficient Treg cells are unstable as defined by their increased production of IL-4 but these Treg cells do not have defects in their ability to maintain Foxp3 expression in a lymphoreplete animal15. Future work will be needed to determine whether mTORC1 signalling is elevated in Itch-deficient Treg cells and whether this contributes to their dysfunction. Future studies on Itch and Ndfip1 will be of particular interest as therapies that activate or inhibit these pathways are being developed. If such therapeutic strategies can be used to regulate Treg cell functions, their use in the clinic could have broad potential.
Ndfip1fl/fl mice47 were crossed to Foxp3-YFP-Cre reporter mice (Jackson Laboratory, stock# 01695917), also referred to as Foxp3-Cre, and bred for only one copy of the Cre gene to generate Ndfip1fl/fl Foxp3-Cre male mice and Ndfip1fl/fl Foxp3-Cre+/− female mice. WT control mice were: Ndfip1+/+ Foxp3-Cre+male, and Ndfip1+/+ Foxp3-Cre +/− female mice. We generated congenic CD45.1/CD45.2 control mice by crossing Ndfip1+/+ Foxp3-Cre+mice to CD45.1 mice (Jackson Laboratory, Stock# 002014). CD45.1 and Rag1−/− are maintained in house. Ndfip1 IL-4 DKO mice25,26 are maintained in house. The gender and ages of mice used are indicated in each figure legend. Mice were maintained in a barrier facility at the Children’s Hospital of Philadelphia. All procedures were approved by the Institutional Care and Use Committee of the Children’s Hospital of Philadelphia. Genotyping primer sequences used were: Ndfip1 flox alleles (Ndfip1 floxed forward 5′-TGAGGAAACAGACACACAATG-3′, Ndfip1 floxed reverse 5′-TGGAATGAACCTGAGGTCTCC-3′)48 and Foxp3-Cre (Jackson Laboratory, stock# 016959, WT Forward: 5′-CCTAGCCCCTAGTTCCAACC-3′, WT Reverse: 5′-AAGGTTCCAGTGCTGTTGCT-3′, Mutant Forward: 5′-AGGATGTGAGGGACTACCTCCTGTA-3′, Mutant Reverse: 5′-TCCTTCACTCTGATTCTGGCAATTT-3′)17. Sequences for Il4 genotyping (Jackson Laboratory, stock# 002253) are: Il4 common 5′-GTGAGCAGATGACATGGGGC-3′; Il4 WT 5′-CTTCAAGCATGGAGTTTTCCC-3′ and Il4 mutant 5′-GCCGATTGTCTGTTGTGCCCAG-3′.
The following flow cytometric antibodies were purchased from Biolegend: CD4 (GK1.5), CD8α (53-6.7), CD44 (IM7), IL-17A (TC11-18H10.1), CD3ɛ (17A2), CD45.2 (104), CD45.1 (A20) GITR (YGITR765), ICOS (C398.4A), and PD-1 (RMP1-30), all used at 1:200 dilution. αYFP/GFP (A-21311) was purchased from Life Technologies and used at 1:400 dilution. Antibodies against IFNγ(XMG1.2) used at 1:300 and Ki67 (B56) used at 1:200 dilution were purchased from BD Biosciences. Biotinylated αphospho-S6 was purchased from Cell Signalling Technologies (D57.2.2E) and used at 1:150 dilution. The remaining antibodies for flow cytometry were purchased from eBioscience: CD25 (PC61.5), CD62L (MEL-14), and IL-10 (JES5-16E3) all used at 1:200 dilution; IL-4 (11B11) used at 1:100 dilution; and Foxp3-biotin (FJK-16s). Biotinylated αFoxp3 and αpS6 were used at 1:150 dilution and detected with fluorophore-conjugated streptavidin at 1:750 dilution (S32354 Invitrogen).
Tissue processing and flow cytometry
Serum was obtained by cardiac puncture immediately following CO2 killing. Spleens and lymph nodes were harvested and mashed through 70 μM nylon filters using cold Hank’s Balanced Salt Solution (HBSS). Spleens were red blood cell (RBC) lysed using ammonium-chloride-potassium lysis buffer, washed, filtered again via a 70 μM filter and resuspended in cold HBSS for sorting or resuspended in complete DMEM (cDMEM) for either phorbol myristate acetate (PMA)/Ionomycin stimulation or direct flow cytometry. Lungs were flushed with cold phosphate-buffered saline (PBS) immediately after killing, minced in cDMEM medium containing 0.9 mg ml−1 of collagenase A (Sigma), 0.8 mg ml−1 of collagenase 1A (Sigma) and 20 μg ml−1 of DNase I (Sigma) and rotated for 1 h at room temperature. FCS was added at 15% v/v and the mixture was filtered through a 100 μM and then 40 μM filter before centrifugation. Lung pellets were RBC lysed using in-house-made ammonium-chloride-potassium lysis buffer, washed, resuspended in complete DMEM media and filtered through a 70 μm filter. The cells were then stimulated for 4 h in 5 ml round bottom polystyrene test tubes with PMA (30 ng ml−1, Calbiochem), ionomycin (1 μM, Abcam) and Brefeldin A (1 μg ml−1, Sigma) for intracellular cytokine staining or directly stained for flow cytometry. For flow cytometry, cells were washed in serum-free HBSS or PBS, stained with live/dead fixable blue dead cell stain (L-23105; Invitrogen, 1:60 dilution), Fc blocked (αCD16/32, 2.4G2; BD Biosciences, 1:25 dilution) and stained with the appropriate antibody mixtures. After staining 25 min at 4 °C, samples were washed in FACs buffer (1xPBS, 2.5% v/v FCS and 0.1%w/v Sodium azide) and then fixed overnight using the Foxp3 Fix/Perm Kit (00-5523-00, eBioscience). After washing with the provided Foxp3 kit perm buffer, intracellular staining was carried out for 1 h at 4 °C. Cells were washed again with perm buffer and resuspended for flow cytometry in FACs buffer. In Fig. 8, expanded Treg cells, cultured as described below, were restimulated with mouse T-cell activator beads (Gibco, 11456D) at a 1:1 cell:bead ratio in complete DMEM medium for 4 h. Samples were immediately fixed at a final concentration of 2% PFA, permeabilized in 90% methanol and then stained for pS6 and surface markers together in Fc block. The same PFA fixation protocol was used for the pSTAT5 experiment. Samples were acquired on an LSRFortessa (BD Biosciences) and analysed using FlowJo version 9.8 (Flowjo LLC). Events analysed were singlets, (FSC-A × FSC-H, SSC-W × SSC-H), live (viability dye negative) and within the lymphocyte gate (FSC-A × SSC-A) (Supplementary Fig. 9).
Enzyme-linked immunosorbent assay (ELISA)
Serum was isolated from 8- to 16-week-old male Ndfip1-sufficient and -deficient Foxp3-Cre+ mice. The concentrations of Ig subclasses in mouse sera were determined using isotype-specific antibodies with a sandwich ELISA protocol. Monoclonal anti-mouse IgA-HRP, IgM-HRP, IgG1-HRP, IgG2C-HRP and IgE-HRP were purchased from SouthernBiotech. These were used in twofold serial dilutions starting at 10 ng ml−1. Flat-bottom, 96-well plate (Nunc) was coated with capture antibody overnight at 1:250 dilution. Plates were blocked with 10% FCS in PBS buffer for 2 h and incubated with sample serum (1:20,000 for IgA, IgM and IgE and 1:40,000 for IgG1 and IgG2C) for 2 h at room temperature and detected with HRP-conjugated Ig subclass antibody (SouthernBiotech, 1:10,000 dilution) for 1 h at room temperature. Plates were developed with TMB substrate solution (eBioscience) and read at 450 nM using a Synergy HT Microplate Reader (BioTek).
YFP+ CD4+ Treg cells were isolated from the spleen and lymph node, enriched for CD4+ T cells by negative selection using 5 μl per mouse of rat αmouse CD8α (2.43; Biolegend,) and 5 μl per mouse of rat αmouse I-A/I-E (M5/114.15.2; Biolegend) in 5–7.5 ml of complete DMEM medium and incubated for 30 min with end-over-end rotation at 4 °C. Cells were then washed and incubated with 1.5 ml of Biomag goat αrat IgG magnetic beads (Qiagen) for 10 min with end-over-end rotation at room temperature; unbound cells were collected using a Dynal magnet (Invitrogen). These enriched and untouched CD4+ T cells were then stained with antibodies against CD4, CD44, CD25 and CD62L all at 1:200 dilution. Cells were filtered through 35 μM filter cap polystyrene FACS tubes (BD Biosciences) and sorted under high speed on a MoFlow Astrios (Beckman Coulter) or a FACS Aria (BD Biosciences). Total Treg cells were sorted as CD4+YFP+, cTreg cells as CD4+YFP+ CD62LhighCD44− and eTreg cells as CD4+YFP+ CD62LlowCD44+. Naive cells were identified as CD4+CD62LhighCD44−CD25−.
Sodium bisulfite conversion, followed by PCR amplification and sequencing of individual clones, was used to determine the extent of CpG DNA methylation at the CNS2 and promoter regions of the Foxp3 gene. First, CD4+YFP+ CD62LlowCD44+eTreg cells were sorted from YFP+ WT and Ndfip1fl/fl Foxp3-Cre+ mice. Naive CD4+ T cells were sorted from WT mice. Next, DNA was extracted using the Qiagen DNeasy Blood and Tissue Kit. Approximately 1 μg of DNA purified from CD4+ Treg cells was bisulfite converted via the following procedure49: the DNA was precipitated in ethanol, washed with 70% ethanol, and resuspended in 20 μl of Tris-EDTA buffer. This DNA was then denatured at 37 °C for 15 min using 0.3 M NaOH and then incubated at 55 °C for 16 h in a mixture containing 5.36 M Urea, 1.72 M sodium metabisulfite and 0.5 mM hydroquinone. The DNA was then desalted using the Wizard DNA clean-up system (Promega, A7170), desulfonated with 0.3 M NaOH, neutralized with 3 M ammonium acetate and precipitated with 100% ethanol. The CNS2 region of the Foxp3 gene was PCR amplified using the following primers: Foxp3 Intron Forward1 5′-GGGTTTTGGGATATTAATATATATAGTAAG-3′, Foxp3 Intron Reverse1 5′-CCACTATATTAACTTAACCCATATAACTAA-3′, Foxp3 Intron Forward2 5′-TTGAGTTTTTGTTATTATAGTATTTGAAGAT-3′, and Foxp3 Intron Reverse2 5′-ACTAAAAACCTAAAAAACTAAACTAACCAA-3′. The promoter region was amplified with the following primers: Foxp3 Promoter Forward1 5′-GTTTGGAGTAGAAGGAAGTTTTTGGAGAT-3′, Foxp3 Promoter Reverse1 5′-TATCTAAAAACCAACTACTCCACCTATCTA-3′, Foxp3 Promoter Forward2 5′-GGTTGTTTTTTATTTATATGGTAGGT-3′, and Foxp3 Promoter Reverse2 5′-CCAAAATCCTTACCTAAAATAACTA-3′. Following nested PCR, bands of appropriate sizes were gel purified and cloned into pGEM-T Easy vector (Promega, A1360). Single colonies were miniprepped with the QIAprep Spin Miniprep DNA Purification Kit (Qiagen, 27104) and sequenced with SP6 primer. Only sequences that were derived from fully converted alleles were used for methylation analysis.
In vitro cell culture
For the in vitro Treg cell suppression assay, sorted naive Tconv CD45.1+ CD4+CD62LhighCD44−CD25− cells were stained with 2.5 μM carboxyfluorescein succinimidyl ester (CFSE) by incubating 400 μl of cells (10-20million cells per ml) in PBS with 400 μl of 5 mM CFSE in PBS solution for 3 min with continuous shaking. Next, 800 μl of FCS was added to the reaction mixture for 30 s at room temperature, followed by adding 10 ml of complete DMEM medium and spinning down in a centrifuge at 1300, r.p.m. for 5 min at 4–6 °C. The CFSE-labelled naive Tconv cells were then resuspended to achieve 1.5 × 104 cells per 50 μl, and 50 μl of these cells were added to the appropriate wells of a 96-well plate. Sorted YFP+ CD4+CD45.2+ Treg cells were resuspended at 1.5 × 104 cells per 50 μl. A total of 50 μl of twofold serial dilutions of these Treg cells were added to the Tconv cells in each well of the 96-well plate to achieve a final Treg:Tconv ratio per well ranging from 0:1 to 1:32 (ref. 50). Next, irradiated bulk CD45.2+ splenocytes (2,500 rads, X-ray irradiator) were resuspended at 1.5 × 105 cells per 50 and 50 μl was added. Last, 50 μl of a 4 × solution containing αCD3 (145-2C11; Biolegend) and rhIL-2 were added to achieve a final concentration of 1 μg ml−1 soluble αCD3 and 50 U ml−1 IL-2 per well. The cells were cultured for 4 days for the suppression assay. For expanded Treg cultures, sorted YFP+ CD4+ total Treg cells or CD4+YFP+ CD62LhighCD44− cTreg cells were resuspended at 1 × 106 cells per ml in media containing 2,000 U ml−1 IL-2 and stimulated at a 1:3 (cell:bead) ratio with mouse αCD3/αCD28 T-cell activator Dynabeads (Gibco, 11456D). After 48 h, cultures were counted and split daily with IL-2 media. Cells were assayed by flow cytometry after 6 or 7 days in cultures. Due to the 48-h activation, results from experiments where we started with sorted YFP+ cTreg cells were virtually identical to those in which we started with sorted YFP+ total Treg cells due to in vitro conversion of c Treg to e Treg cells. We therefore present all of that data pooled together. For analysis of RNA, expanded Treg cells were restimulated on day 7 of culture at a 1:1 ratio with αCD3/CD28 beads for the indicated periods. Supernatant was saved for ELISA and cells were harvested for quantitative PCR (qPCR). For cocultures, sorted WT and Ndfip-1 deficient Treg cells were mixed in a 1:1 ratio before being plated. For the in vitro stability assay using IL-2, IL-4 and αIL-2, WT or Ndfip1-deficient YFP+ Treg cells were sorted from matched male or female donors. The Treg cells were cultured for 96 h on plate-bound 5 μg ml−1 αCD3/αCD28 and either 500 U ml−1 IL-2 or 20 ng ml−1 IL-4 with 20 ng ml−1 α-IL-2. All cultured cells, unless otherwise noted, were cultured at 10% CO2 in complete T-cell medium, that is, DMEM (Mediatech) supplemented with 10% FCS (Atlanta Biologicals, premium FCS), 1% pen/strep (Invitrogen), 1% Glutamax (Invitrogen), 1% Minimum Essential Medium–non-essential amino acids (Invitrogen), 20 mM HEPES (Invitrogen), 1 mM Sodium Pyruvate and 0.12 mM betamercaptoethanol (Sigma) supplemented with recombinant human 50 U ml−1 IL-2 (originally obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health).
Metabolic function assays
YFP+ CD44−CD62L+ Treg cells (cTreg cells ) or YFP+ CD4+ Treg cells (total Treg cells ) were sorted from 7- to 12-week-old, age-matched male or female, congenically marked CD45.1 WT or CD45.2 Ndfip1fl/fl Foxp3-Cre+ (cKO) mice. After sorting, the WT or cKO Treg cells were expanded at a 1:3 (cell:bead) ratio with mouse αCD3/αCD28 beads for 7 days. On day 7, cells were harvested and resuspended at 5 × 106 cells per ml in appropriate Seahorse media. In all, 40 μl of cells were added to 140 μl of appropriate seahorse media or 140 μl of Seahorse media containing fresh mouse αCD3/αCD28 beads at a 1:1 (cell:bead) ratio. Cells were plated in XF96 cell culture microplates that were precoated with 25 μl of Cell tak reagent overnight according to the manufacturer’s instructions (Corning, 354240).
For examining glycolysis, the glyco-stress test kit (Seahorse Bioscience) was used with additions of the following reagents to cells in glucose-free Seahorse media: 10 mM glucose, 2 μM oligomycin, and 50 mM 2-DG. To determine the rate of glycolysis, Treg cells were incubated in glucose-free medium and the increased extracellular acidification rate response upon stimulation of glycolysis by glucose and oligomycin was determined. Oligomycin inhibits mitochondrial ATP synthase (complex V) forcing glycolysis to compensate for the lack of ATP production in oxidative phosphorylation. Finally, 2-dexoglucose was added to inhibit glycolysis. For examining mitochondrial function, a mito-stress kit was used with additions of the following reagents to cells in appropriate Seahorse media: 2 μM Oligomycin, 1.5 μM fluoro-carbonyl cyanide phenylhydrazone (an uncoupler of respiration and oxidative ATP synthesis), and premixed 100 nM rotenone+1 μM antimycin A solution (Electron Transport Chain complex I and III inhibitors). Plates were run on an XF96 Seahorse assay instrument. Settings used were: calibration, equilibration, and baseline readings (loop three times). Before the baseline reading, and after each injection from a port, the following procedure was followed: mix, wait 3 min, and measure for 2 min with 3 min end loop51. Each reagent was added according to the volumes recommended by the Seahorse assay manufacturer.
Samples for qPCR were lysed in Trizol (Ambion). RNA was extracted using chloroform and qPCR was performed as follows: 10 ng of cDNA was added to TaqMan Gene Expression Master Mix and TaqMan Gene Expression primer/probe mix specific for Ndfip1 (Applied Biosystems), according to the manufacturer’s protocol for a final reaction volume of 20 μl. qPCR was performed using an Applied Biosystems 7500 Real-Time PCR system. Each sample was assayed in triplicate along with the endogenous control (actin). Actb primer/probe (4352933E) was obtained from Applied Biosystems. Ndfip1 custom primers: Ndfip1_F 5′-GCTCCTCCACCATACAGCAGC-3′; Ndfip1_R 5′-CGATGGGGGCTTTGGAAATCCAG-3′, and Ndfip1 Taqman MGB probe: 5′-TTTGGAAATCCAGATTCATCTTTG-3′ were obtained from Applied Biosystems40. Relative mRNA expression of each gene of interest was calculated as 2dCt, where dCt represents threshold cycle (Ct) of Actin beta minus Ct of gene of interest.
Bone marrow chimeras
Bone marrow from male Ndfip1fl/fl Foxp3-Cre+ (CD45.2+) or WT mice: Ndfip1+/+ Foxp3-Cre+ (CD45.1/CD45.2) or CD45.1+ mice was obtained by flushing femur and tibia with cold HBSS, RBC lysing and passing through a 70 μM filter. Cells were processed into a single-cell suspension, T cell depleted, resuspended in freezing media (90% FCS, 10% DMSO) and kept at −80 °C until used. Thawed cells were washed, counted, resuspended in sterile PBS, mixed 1:1 CD45.1:CD45.2 and injected intravenously into sublethally irradiated (400 rads, X-Ray irradiator) 6-week-old male Rag1−/− recipients at 1 × 106 cells per mouse. Chimeras were kept on 5.3 ml of Trimethoprim/Sulfamethoxazole (200 mg sulfamethoxazole+40 mg trimethoprim per 5 ml) per 400 ml drinking water for the first 2 weeks after bone marrow transfer. Chimeras were analysed 8 weeks after transfer.
Skin (ear) and oesophagus were dissected and fixed in 10% neutral buffered formalin for at least 24 h. Lung were obtained after manual transcardial perfusion with 10 ml syringes containing PBS and fixed in 10% neutral buffered formalin. All organs were then embedded in paraffin, sectioned to 5 μm thickness and stained with Haematoxylin and Eosin. Images were obtained using a Leica DM4000B upright scope paired with a Spot RT/SE Slider camera (Children’s Hospital of Philadelphia Pathology Core).
T-cell transfer colitis
Naive CD4+ T cells from WT mice (CD45.1+ or CD45.1/CD45.2) and CD4+YFP+ Treg cells from CD45.2+ Ndfip1fl/fl Foxp3-Cre and CD45.2+ Ndfip1+/+ Foxp3-Cre male mice were isolated from the spleens and lymph nodes. Cells were resuspended in sterile PBS and congenic naive T cells were mixed at a 5:1 ratio with YFP+ Treg cells. A total of 0.36 × 106 cells were injected intraperitoneally into 6–8-week-old Rag1−/− mice. Mice were weighed weekly. Recipients of both genotypes were cohoused. At killing, mice were weighed, spleens were weighed and the spleens and lung were processed for flow cytometry as described above. A fraction of the total lung/spleen single-cell suspensions were stained with antibodies against CD4, CD45.1 and CD45.2 and sorted using a Moflow Astrios as described above for analysis of Ndfip1 mRNA in cells from Ndfip1fl/fl Foxp3-Cre and Ndfip1+/+ Foxp3-Cre donor Treg cells. Sorted cells were CD4+CD45.2+CD45.1−YFP+ (current Treg cells ) or CD4+CD45.2+CD45.1−YFP− (former Treg cells) or CD4+CD45.2−CD45.1+ YFP- (Tconv cells). Cells were stimulated for 5 h with plate-bound 5 μg ml−1 αCD3/CD28 at 3 × 105 cells per ml and harvested in Trizol for qPCR. The remaining fractions of total lung/spleen single-cell suspensions were either stained directly for flow cytometry or stimulated for 4 h with PMA/ionomycin in the presence of Brefeldin A to analyse cytokine production by flow cytometry.
Preparation of lysates for whole-cell proteome analysis
Ndfip1-sufficient and -deficient cTreg cells and eTreg cells were isolated and lysed using a lysis buffer containing 100 mM Tris-HCl, pH 8.0, 0.15 M NaCl, 5 mM EDTA, 1% NP-40, 0.5% Triton-X 100, protease inhibitor cocktail (Roche, 11697498001), 5 mM of 1,10-phenyanthroline (o-PA), 5 mM N-ethymaleimide and 0.1 mM PR-619. In all, 10 μl of lysis buffer was used for every 10 × 106 cells. Protein was quantified by BCA (Pierce, 23227). Approximately 15 μg of lysate was mixed 1:1 with 4 × Laemmli sample buffer for whole proteome analysis. Samples were boiled and run ∼2 cm past the stacking gel in 10% Criterion precast Tris-HCL gels (Biorad). Gels were fixed overnight and stained briefly with Coomassie blue. Each lane of the Coomassie-stained gel was divided into 8–10 2 × 9 mm2 ‘pixels,’ each cut into 1 mm3 cubes52. They were destained with 50% Methanol/1.25% Acetic Acid, reduced with 5 mM dithiothreitol (Thermo) and alkylated with 40 mM iodoacetamide (Sigma). Gel pieces were then washed with 20 mM ammonium bicarbonate (Sigma) and dehydrated with acetonitrile (Fisher). Trypsin (5 ng μl−1 in 20 mM ammonium bicarbonate, Promega) was added to the gel pieces and proteolysis was allowed to proceed overnight at 37 °C. Peptides were extracted with 0.3% triflouroacetic acid (J.T. Baker), followed by 50% acetonitrile. Extracts were combined and the volume was reduced by vacuum centrifugation.
Mass spectrometric analysis
Tryptic digests were analysed by LC-MS/MS on a hybrid LTQ Orbitrap Elite mass spectrometer coupled with a Dionex Ultimate 3000 (Thermofisher Scientific San Jose, CA). Peptides were separated by reverse phase (RP) HPLC on a nanocapillary column, 75 μm id × 30 cm Reprosil-pur 1.9 μM (Dr Maisch, Germany). Mobile phase A consisted of 0.1% formic acid (Thermo) and mobile phase B of 0.1% formic in acetonitrile. Peptides were eluted into the mass spectrometer at 300 nl min−1 with each RP-LC run comprising a 90 min gradient from 3% to 45% B in 90 min. The mass spectrometer was set to repetitively scan m/z from 300 to 1,800 (R=240,000 for LTQ-Orbitrap Elite) followed by data-dependent MS/MS scans on the 20 most abundant ions, with a minimum signal of 1,500, dynamic exclusion with a repeat count of 1, repeat duration of 30 s, exclusion size of 5,000 and duration of 60 s, isolation width of 2.0, normalized collision energy of 33 and waveform injection and dynamic exclusion enabled. Fourier transform MS full-scan AGC target value was 1e6, while MSn AGC was 1e4. Fourier transform MS full-scan maximum fill time was 10 ms, while ion trap MSn fill time was 100 ms; microscans were set at one. FT preview mode; charge state screening and monoisotopic precursor selection were all enabled with rejection of unassigned and 1+ charge states.
Proteomic data analysis
Proteomic data were analysed using Maxquant version 220.127.116.11 searching against the Uniprot complete mouse reference proteome, including isoforms, (updated 19 September 2013) and common laboratory contaminants. A minimum peptide length of six amino acids and a peptide and protein false discovery of 1% was required. The three biological replicates for Ndfip1-sufficient and -deficient eTreg cells and cTreg cells were analysed together, with match between runs and requantify turned on. Label-free quantification via intensity-based absolute quantification was calculated in MaxQuant. Quantification data were normalized by the mean quantification value of identified proteins in each replicate and log2 transformed. Comparisons of protein hits from WT or Ndfip1-deficient eTreg or cTreg cells were calculated by log2 fold changes and evaluated for significance using a one-sample t-test. Area-proportional Venn diagrams were generated with eulerAPE version 3.0 (http://www.eulerdiagrams.org/eulerAPE/)53. The GO analysis and corresponding network diagram in Fig. 6e was generated with the BiNGO application54 in Cytoscape55. The differentially regulated proteins identified in WT vs cKO eTreg comparisons were compared against the Mus musculus GO Biological Process annotation using a hypergeometric significance test with Benjamini–Hochberg false-discovery rate correction. A threshold of adjusted P value of <0.01 was required for enrichment.
Data were graphed and analysed for statistical significance in Prism version 6 or version 7 (Graphpad Software, Inc) or Excel (Microsoft). The heatmap in Fig. 5 was generated in prism 7. The following statistical tests were used as appropriate and as noted in the figure legends: t-test, one-way analysis of variance (ANOVA), two-way ANOVA, and repeated-measures ANOVA. All data are shown as average±s.e.m., with a cutoff of P<0.05 for statistical significance: *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001.
All data generated or analysed during this study are included in this published article (and its Supplementary Information files). The mass spectrometric proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE56 partner repository with the data set identifier PXD006251.
How to cite this article: Layman, A. A. K. et al. Ndfip1 restricts mTORC1 signalling and glycolysis in regulatory T cells to prevent autoinflammatory disease. Nat. Commun. 8, 15677 doi: 10.1038/ncomms15677 (2017).
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We thank Steve Seeholzer, Hossein Fazelinia, Hua Ding and Lynn Spruce of the Children’s Hospital of Philadelphia Research protein core. We thank Stephanie Sprout for mouse colony management. This work was supported by the National Institutes of Health Grants R01AI093566 and R01AI114515 to P.M.O.; T32CA009140-39 to A.A.K.L.; the American Asthma Foundation Grant 13-0020 to P.M.O.; and by the University of Pennsylvania Diabetes Center Islet Cell Biology Core P30-DK19525 to N.M.D.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/